Literature DB >> 25210719

DNA vaccines against influenza.

Anna Stachyra1, Anna Góra-Sochacka1, Agnieszka Sirko1.   

Abstract

Genetic vaccine technology has been considerably developed within the last two decades. This cost effective and promising strategy can be applied for therapy of cancers and for curing allergy, chronic and infectious diseases, such as a seasonal and pandemic influenza. Despite numerous advantages, several limitations of this technology reduce its performance and can retard its commercial exploitation in humans and its veterinary applications. Inefficient delivery of the DNA vaccine into cells of immunized individuals results in low intracellular supply of suitable expression cassettes encoding an antigen, in its low expression level and, in turn, in reduced immune responses against the antigen. Improvement of DNA delivery into the host cells might significantly increase effectiveness of the DNA vaccine. A vast array of innovative methods and various experimental strategies have been applied in order to enhance the effectiveness of DNA vaccines. They include various strategies improving DNA delivery as well as expression and immunogenic potential of the proteins encoded by the DNA vaccines. Researchers focusing on DNA vaccines against influenza have applied many of these strategies. Recent examples of the most successful modern approaches are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25210719

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  13 in total

1.  Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.

Authors:  Ingrid Karlsson; Marie Borggren; Jens Nielsen; Dennis Christensen; Jim Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2017-06-14       Impact factor: 3.452

Review 2.  Micro- and nanoparticulates for DNA vaccine delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-04

Review 3.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

Review 4.  Recent outbreaks of highly pathogenic avian influenza viruses in South Korea.

Authors:  Hye Kwon Kim; Dae Gwin Jeong; Sun-Woo Yoon
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26

5.  Response to a DNA vaccine against the H5N1 virus depending on the chicken line and number of doses.

Authors:  Barbara Małgorzata Kalenik; Anna Góra-Sochacka; Anna Stachyra; Monika Olszewska-Tomczyk; Anna Fogtman; Róża Sawicka; Krzysztof Śmietanka; Agnieszka Sirko
Journal:  Virol J       Date:  2020-05-07       Impact factor: 4.099

6.  Effective usage of cationic derivatives of polyprenols as carriers of DNA vaccines against influenza virus.

Authors:  Anna Stachyra; Monika Rak; Patrycja Redkiewicz; Zbigniew Madeja; Katarzyna Gawarecka; Tadeusz Chojnacki; Ewa Świeżewska; Marek Masnyk; Marek Chmielewski; Agnieszka Sirko; Anna Góra-Sochacka
Journal:  Virol J       Date:  2017-09-02       Impact factor: 4.099

7.  Immunogenicity of DNA Vaccine against H5N1 Containing Extended Kappa B Site: In Vivo Study in Mice and Chickens.

Authors:  Patrycja Redkiewicz; Anna Stachyra; Róz A Sawicka; Katarzyna Bocian; Anna Góra-Sochacka; Piotr Kosson; Agnieszka Sirko
Journal:  Front Immunol       Date:  2017-08-24       Impact factor: 7.561

Review 8.  A Review of DNA Vaccines Against Influenza.

Authors:  Leo Yi Yang Lee; Leonard Izzard; Aeron C Hurt
Journal:  Front Immunol       Date:  2018-07-09       Impact factor: 7.561

Review 9.  Efforts to Improve the Seasonal Influenza Vaccine.

Authors:  Alfred T Harding; Nicholas S Heaton
Journal:  Vaccines (Basel)       Date:  2018-03-30

10.  Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens.

Authors:  Anna Stachyra; Patrycja Redkiewicz; Piotr Kosson; Anna Protasiuk; Anna Góra-Sochacka; Grzegorz Kudla; Agnieszka Sirko
Journal:  Virol J       Date:  2016-08-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.